Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

401

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

February 1, 2028

Conditions
Multiple Myeloma
Interventions
DRUG

Daratumumab plus Velcade Cyclophosphamide Dexamethasone

To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.

DRUG

Velcade Thalidomide Dexamethasone

To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.

Trial Locations (3)

28100

A.O.U. Maggiore della Carità di Novara, Novara

708 52

University Hospital Ostrava, Ostrava

115 28

"General Hospital of Athens Alexandra", Athens

All Listed Sponsors
collaborator

EMN Trial Office S.r.l. Impresa Sociale

OTHER

lead

Stichting European Myeloma Network

NETWORK